Risk factors for gastrointestinal complications during glucocorticoid therapy in internal medicine inpatients: a real-world retrospective analysis.

IF 2.8 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Pengpeng Liu, Guangyao Li, Qinglin Yang, Kai Cao, Jiawei Wang
{"title":"Risk factors for gastrointestinal complications during glucocorticoid therapy in internal medicine inpatients: a real-world retrospective analysis.","authors":"Pengpeng Liu, Guangyao Li, Qinglin Yang, Kai Cao, Jiawei Wang","doi":"10.1186/s40360-025-00871-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The risk factors for gastrointestinal complications during glucocorticoid therapy in internal medicine inpatients are rarely reported. This study aimed to investigate the risk factors for gastrointestinal complications in internal medicine patients using glucocorticoids.</p><p><strong>Methods: </strong>Internal medicine inpatients receiving glucocorticoid therapy from February 2023 to September 2023 were included. Gastrointestinal complications were identified by careful review of the electronic medical records of these patients. The risk factors for gastrointestinal complications during glucocorticoid therapy were analyzed by univariable and multivariable logistic regression. Receiver operating characteristic (ROC) curve with Youden's index was used to determine the best cutoff point of the identified continuous variables.</p><p><strong>Results: </strong>Of the 960 inpatients included, 88 had gastrointestinal complications, with the most common complications including 27 (30.7%) with abdominal discomfort, 26 (29.5%) with acid regurgitation and heartburn, and 14 (15.9%) with asymptomatic positive fecal occult blood. Multiple logistic regression analysis showed that age ≥ 65 years [OR = 2.014, 95% CI (1.096, 3.703), p = 0.024], history of gastroesophageal reflux disease (GERD) [OR = 1.810, 95% CI (1.009, 3.250), p = 0.047], history of peptic ulcer (PU) [OR = 5.636, 95% CI (1.505, 21.102), p = 0.010], maximum dose of glucocorticoids [OR = 1.003, 95% CI (1.001, 1.004), p = 0.001], and nonsteroidal anti-inflammatory drugs (NSAIDs) [OR = 2.788, 95% CI (1.023, 7.597), p = 0.045] were associated with more gastrointestinal complications during glucocorticoid therapy in internal medicine inpatients. ROC curve analysis revealed that when the maximum dose of glucocorticoids was greater than 160 mg, gastrointestinal complications were more likely to occur.</p><p><strong>Conclusions: </strong>The study shows that age ≥ 65 years, history of GERD, history of PU, maximum dose of glucocorticoids, and NSAIDs are associated with more gastrointestinal complications during glucocorticoid therapy in internal medicine inpatients. Multidisciplinary teams, including physicians, pharmacists, and nurses, should consider increased monitoring to inpatients with high-risk factors.</p>","PeriodicalId":9023,"journal":{"name":"BMC Pharmacology & Toxicology","volume":"26 1","pages":"37"},"PeriodicalIF":2.8000,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11841309/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Pharmacology & Toxicology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s40360-025-00871-w","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The risk factors for gastrointestinal complications during glucocorticoid therapy in internal medicine inpatients are rarely reported. This study aimed to investigate the risk factors for gastrointestinal complications in internal medicine patients using glucocorticoids.

Methods: Internal medicine inpatients receiving glucocorticoid therapy from February 2023 to September 2023 were included. Gastrointestinal complications were identified by careful review of the electronic medical records of these patients. The risk factors for gastrointestinal complications during glucocorticoid therapy were analyzed by univariable and multivariable logistic regression. Receiver operating characteristic (ROC) curve with Youden's index was used to determine the best cutoff point of the identified continuous variables.

Results: Of the 960 inpatients included, 88 had gastrointestinal complications, with the most common complications including 27 (30.7%) with abdominal discomfort, 26 (29.5%) with acid regurgitation and heartburn, and 14 (15.9%) with asymptomatic positive fecal occult blood. Multiple logistic regression analysis showed that age ≥ 65 years [OR = 2.014, 95% CI (1.096, 3.703), p = 0.024], history of gastroesophageal reflux disease (GERD) [OR = 1.810, 95% CI (1.009, 3.250), p = 0.047], history of peptic ulcer (PU) [OR = 5.636, 95% CI (1.505, 21.102), p = 0.010], maximum dose of glucocorticoids [OR = 1.003, 95% CI (1.001, 1.004), p = 0.001], and nonsteroidal anti-inflammatory drugs (NSAIDs) [OR = 2.788, 95% CI (1.023, 7.597), p = 0.045] were associated with more gastrointestinal complications during glucocorticoid therapy in internal medicine inpatients. ROC curve analysis revealed that when the maximum dose of glucocorticoids was greater than 160 mg, gastrointestinal complications were more likely to occur.

Conclusions: The study shows that age ≥ 65 years, history of GERD, history of PU, maximum dose of glucocorticoids, and NSAIDs are associated with more gastrointestinal complications during glucocorticoid therapy in internal medicine inpatients. Multidisciplinary teams, including physicians, pharmacists, and nurses, should consider increased monitoring to inpatients with high-risk factors.

内科住院患者糖皮质激素治疗期间胃肠道并发症的危险因素:现实世界回顾性分析。
背景:内科住院患者糖皮质激素治疗过程中发生胃肠道并发症的危险因素报道较少。本研究旨在探讨使用糖皮质激素的内科患者胃肠道并发症的危险因素。方法:纳入2023年2月至2023年9月住院接受糖皮质激素治疗的内科患者。通过仔细审查这些患者的电子医疗记录,确定了胃肠道并发症。采用单变量和多变量logistic回归分析糖皮质激素治疗期间胃肠道并发症的危险因素。采用约登指数的受试者工作特征(ROC)曲线确定识别出的连续变量的最佳截止点。结果960例住院患者中,有胃肠道并发症88例,最常见的并发症为腹部不适27例(30.7%),反酸胃灼热26例(29.5%),无症状粪便隐血阳性14例(15.9%)。多元逻辑回归分析表明,年龄≥65岁(OR = 2.014, 95% CI (1.096, 3.703), p = 0.024),胃食管反流病(GERD)的历史(OR = 1.810, 95% CI (1.009, 3.250), p = 0.047),历史的消化性溃疡(PU) (OR = 5.636, 95% CI (1.505, 21.102), p = 0.010),最大剂量的糖皮质激素(OR = 1.003, 95% CI (1.001, 1.004), p = 0.001),及非甾体类抗炎药(非甾体抗炎药)(OR = 2.788, 95% CI (1.023, 7.597),P = 0.045]与内科住院患者糖皮质激素治疗期间胃肠道并发症发生率相关。ROC曲线分析显示,当糖皮质激素的最大剂量大于160 mg时,更容易发生胃肠道并发症。结论:研究表明,年龄≥65岁、有GERD史、PU史、糖皮质激素最大剂量和非甾体抗炎药与内科住院患者糖皮质激素治疗期间胃肠道并发症的发生率相关。包括医生、药剂师和护士在内的多学科团队应考虑加强对有高危因素的住院患者的监测。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
BMC Pharmacology & Toxicology
BMC Pharmacology & Toxicology PHARMACOLOGY & PHARMACYTOXICOLOGY&nb-TOXICOLOGY
CiteScore
4.80
自引率
0.00%
发文量
87
审稿时长
12 weeks
期刊介绍: BMC Pharmacology and Toxicology is an open access, peer-reviewed journal that considers articles on all aspects of chemically defined therapeutic and toxic agents. The journal welcomes submissions from all fields of experimental and clinical pharmacology including clinical trials and toxicology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信